Alzex Neuropharma Inc.
TRRI
$0.12
$0.11889,900.00%
| Weiss Ratings | TRRI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Unrated | |||
| Risk Index | Unrated | |||
| Risk Grade | U | |||
| Reward Grade | U | |||
| Rating Factors | TRRI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Unrated | |||
| Growth Index | Unrated | |||
| Efficiency Index | Unrated | |||
| Solvency Index | Unrated | |||
| Total Return Index | Unrated | |||
| Volatility Index | Unrated | |||
| Beta / Standard Deviation | TRRI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.34 | |||
| Price History | TRRI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 137.62% | |||
| 30-Day Total Return | 126.42% | |||
| 60-Day Total Return | -50.00% | |||
| 90-Day Total Return | 8.01% | |||
| Year to Date Total Return | -39.39% | |||
| 1-Year Total Return | 9.09% | |||
| 2-Year Total Return | -58.62% | |||
| 3-Year Total Return | -52.00% | |||
| 5-Year Total Return | -14.47% | |||
| 52-Week High % Change | -60.40% | |||
| 52-Week Low % Change | 9,900.00% | |||
| Price | TRRI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.30 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Feb 27, 2025 | |||
| 52-Week High Price (Date) | Nov 25, 2024 | |||
| Valuation | TRRI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 180.63K | |||
| Enterprise Value | -- | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -- | |||
| Earnings Per Share Growth | -- | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -- | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.12 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -- | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | TRRI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | -- | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | TRRI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 310-435-0435 | |||
| Address | 8275 S. Eastern Avenue Las Vegas, NV 89123 | |||
| Website | www.trinresinc.com | |||
| Country | United States | |||
| Year Founded | 1971 | |||
| Profitability | TRRI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 2.66% | |||
| Profit Margin | 2.39% | |||
| Management Effectiveness | TRRI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 3.44% | |||
| Return on Equity | 11.64% | |||
| Income Statement | TRRI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 3.96M | |||
| Total Revenue (TTM) | 4.00M | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | 420.80K | |||
| EBITDA (TTM) | -48.90K | |||
| EBIT (TTM) | 106.60K | |||
| Net Income (TTM) | 95.60K | |||
| Net Income Avl. to Common (TTM) | 95.60K | |||
| Total Revenue Growth (Q YOY) | 23.58% | |||
| Earnings Growth (Q YOY) | -68.31% | |||
| EPS Diluted (TTM) | -- | |||
| EPS Diluted Growth (Q YOY) | -- | |||
| Balance Sheet | TRRI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 63.50K | |||
| Cash Per Share (Q) | -- | |||
| Total Current Assets (Q) | 199.70K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 904.10K | |||
| Current Ratio (Q) | 0.998 | |||
| Book Value Per Share (Q) | -- | |||
| Total Assets (Q) | -- | |||
| Total Current Liabilities (Q) | 200.10K | |||
| Total Debt (Q) | -- | |||
| Total Liabilities (Q) | -- | |||
| Total Common Equity (Q) | 904.10K | |||
| Cash Flow | TRRI - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | -221.90K | |||
| Net Change in Cash (TTM) | 108.80K | |||
| Levered Free Cash Flow (TTM) | 197.70K | |||
| Cash from Operations (TTM) | 330.70K | |||
